The invention discloses a drug for treating pharyngeal neurasthenia, and belongs to the field of traditional Chinese medicines. The effective constituents of the drug comprise the following raw materials in parts by weight: 45-65 parts of liquorice, 45-60 parts of caulis perllae, 40-60 parts of poria cocos, 35-55 parts of prepared pinellia tuber, 35-40 parts of white paeony root, 30-50 parts of blackberry lily, 25-45 parts of fingered citron, 25-40 parts of mangnolia officinalis, 20-35 parts of pericarpium citri reticulatae, 15-35 parts of radix aconiti lateralis preparata, 15-30 parts of radix curcumae, 15-25 parts of polygala tenuifolia, 10-25 parts of yam, 10-20 parts of costustoot, 5-15 parts of radix linderae and 5-10 parts of flos mume. According to the invention, the raw materials are reasonably selected for pathogenic factors such as phlegm-damp middle occlusion, phlegm vital energy upward reversal, seven-emotion stagnation, vital energy stagnation and phlegm congealing and the like; and the drug is prepared by scientifically mixing the Chinese herbal medicines, has the effects of promoting the circulation of vital energy to remove stasis, clearing throat to benefit diaphragm, regulating vital energy to dispel melancholy and calming the adverse-rising energy to reduce phlegm, has a good absorption effect, avoids toxic and side effects and adverse reactions, and has a good treatment effect for the pharyngeal neurasthenia.